Plain-English translation of NCT07141303 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether methylprednisolone sodium succinate, a steroid medication, can help people recover better after successful emergency surgery to remove a blood clot from the brain. You would receive this medication either through an artery during the surgery and then through an IV for the next 3 days, or a placebo (inactive treatment). The goal is to see if this approach reduces disability and improves outcomes after stroke.
After emergency clot-removal surgery, the brain can experience inflammation and further damage. Researchers want to know if giving this medication early might reduce that inflammation and help people recover better than with current standard care alone.
You likely qualify if…
You likely don't qualify if…
After your emergency clot-removal surgery, you will be randomly assigned to receive either the steroid medication or a placebo. If assigned to the treatment group, you'll receive the medication directly into an artery immediately after surgery, then continue with IV doses over the next 3 days. You'll be monitored closely during your hospital stay and have follow-up evaluations to track your recovery and check for any side effects. The whole study involves standard stroke care plus this additional treatment protocol.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China